The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

CHICAGO — In patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, chronic kidney disease, or both, the oral formulation of semaglutide, a glucagon-like ...